Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Colorectal Cancer, Liver Cancer, Cancer, Cancer, Cancer, Cancer, Pancreatic Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 99 |
| Updated: | 4/6/2019 |
| Start Date: | April 10, 2019 |
| End Date: | December 31, 2022 |
| Contact: | Maureen F Connolly |
| Email: | maureen.connolly@nih.gov |
| Phone: | (240) 858-3734 |
Background:
Gastrointestinal tumors have a molecule called CA19-9 in the tumors and blood. The agent
MVT-5873 was designed to block this molecule. Researchers want to test how safe it is to give
this agent to people before and after surgery to remove a tumor. They want to learn the
highest dose tolerated. They want to see if getting the agent at surgery helps slow down the
disease.
Objective:
To test the safety of giving MVT-5873 at surgery to remove cancer and see if it slows the
progression of the disease.
Eligibility:
Adults at least 18 years old with certain cancers and certain blood CA19-9 levels
Design:
Participants will be screened with:
- Medical history
- Physical exam
- Blood and heart tests
- Scans
- Review of normal activities
- Review of tumor sample
- Pregnancy test
A few days before surgery, participants will get a dose of the study agent. They will get it
through a small plastic tube in a vein over about 2 hours.
Participants will sign a separate consent and have the surgery. A sample of the tumor and
normal liver will be removed for research.
For 1-2 weeks after surgery, participants will recover in intensive care then regular care at
the hospital. They will be monitored and treated throughout the stay.
After leaving the hospital, participants will get the study agent every week for 1 month.
Then they will get it every other week for 2 months. They will repeat screening tests at
study visits and at a follow-up visit. That will be about 5 weeks after the last dose.
Gastrointestinal tumors have a molecule called CA19-9 in the tumors and blood. The agent
MVT-5873 was designed to block this molecule. Researchers want to test how safe it is to give
this agent to people before and after surgery to remove a tumor. They want to learn the
highest dose tolerated. They want to see if getting the agent at surgery helps slow down the
disease.
Objective:
To test the safety of giving MVT-5873 at surgery to remove cancer and see if it slows the
progression of the disease.
Eligibility:
Adults at least 18 years old with certain cancers and certain blood CA19-9 levels
Design:
Participants will be screened with:
- Medical history
- Physical exam
- Blood and heart tests
- Scans
- Review of normal activities
- Review of tumor sample
- Pregnancy test
A few days before surgery, participants will get a dose of the study agent. They will get it
through a small plastic tube in a vein over about 2 hours.
Participants will sign a separate consent and have the surgery. A sample of the tumor and
normal liver will be removed for research.
For 1-2 weeks after surgery, participants will recover in intensive care then regular care at
the hospital. They will be monitored and treated throughout the stay.
After leaving the hospital, participants will get the study agent every week for 1 month.
Then they will get it every other week for 2 months. They will repeat screening tests at
study visits and at a follow-up visit. That will be about 5 weeks after the last dose.
Background:
- Resections to remove tumors in the liver, bile ducts and pancreas are rarely curative,
and patients frequently succumb to disease recurrence in the ensuing months to year(s)
after the operation.
- Standard adjuvant therapies, which typically begin 6-12 weeks after surgery, offer
little demonstrable decreases in the rates of tumor recurrence.
- The concept and implementation of immediate perioperative therapy has not been evaluated
given the serious concerns related to healing and recovery with standard cytotoxic
chemotherapy and newer targeted agents.
- A significant percentage of metastatic colorectal cancers, and primary tumors of the
pancreas and bile ducts express Sialyl Lewis, an epitope on the well-established tumor
marker, CA 19-9.
- MVT-5873, a fully human antibody against Sialyl Lewis, has displayed ADCC and CDC in
vitro, potentiated chemotherapeutic efficacy in mouse models and demonstrated efficacy
in Phase 1 trials of patients with advanced inoperable HPB cancer.
- MVT-5873 is well tolerated as a single agent; moderate elevations in AST/ALT appear to
be dose-limiting.
- Patients with resectable Sialyl Lewis-expressing cancers represent an ideal population
to explore the use of perioperative MVT-5873 given moderate level of CA 19-9 elevations,
and the potential for extension of recurrence-free survival.
Objectives:
- Document the safety of perioperative MVT-5873 in patients undergoing pancreas and liver
resections.
- Determine if perioperative MVT-5873 can decrease 1-year recurrence rates for patients
with operable CA 19-9-producing cancers.
Eligibility:
- Histologically or cytologically confirmed adenocarcinoma of the
- Colon (metastatic to liver)
- Pancreas
- Bile Ducts (Cholangiocarcinoma)
- Serum CA19-9 levels greater than the upper limit of normal, but less than 2500.
- Disease amenable to complete surgical extirpation.
Design:
-Pre-operative one-time treatment with MVT-5873, resection to remove all demonstrable disease
in the liver, bile ducts and pancreas, and continuing MVT-5873 mono-therapy until off
treatment criteria are met.
- Resections to remove tumors in the liver, bile ducts and pancreas are rarely curative,
and patients frequently succumb to disease recurrence in the ensuing months to year(s)
after the operation.
- Standard adjuvant therapies, which typically begin 6-12 weeks after surgery, offer
little demonstrable decreases in the rates of tumor recurrence.
- The concept and implementation of immediate perioperative therapy has not been evaluated
given the serious concerns related to healing and recovery with standard cytotoxic
chemotherapy and newer targeted agents.
- A significant percentage of metastatic colorectal cancers, and primary tumors of the
pancreas and bile ducts express Sialyl Lewis, an epitope on the well-established tumor
marker, CA 19-9.
- MVT-5873, a fully human antibody against Sialyl Lewis, has displayed ADCC and CDC in
vitro, potentiated chemotherapeutic efficacy in mouse models and demonstrated efficacy
in Phase 1 trials of patients with advanced inoperable HPB cancer.
- MVT-5873 is well tolerated as a single agent; moderate elevations in AST/ALT appear to
be dose-limiting.
- Patients with resectable Sialyl Lewis-expressing cancers represent an ideal population
to explore the use of perioperative MVT-5873 given moderate level of CA 19-9 elevations,
and the potential for extension of recurrence-free survival.
Objectives:
- Document the safety of perioperative MVT-5873 in patients undergoing pancreas and liver
resections.
- Determine if perioperative MVT-5873 can decrease 1-year recurrence rates for patients
with operable CA 19-9-producing cancers.
Eligibility:
- Histologically or cytologically confirmed adenocarcinoma of the
- Colon (metastatic to liver)
- Pancreas
- Bile Ducts (Cholangiocarcinoma)
- Serum CA19-9 levels greater than the upper limit of normal, but less than 2500.
- Disease amenable to complete surgical extirpation.
Design:
-Pre-operative one-time treatment with MVT-5873, resection to remove all demonstrable disease
in the liver, bile ducts and pancreas, and continuing MVT-5873 mono-therapy until off
treatment criteria are met.
- INCLUSION CRITERIA:
- Subjects must have histologically or cytologically confirmed diagnoses of
adenocarcinoma in one of the following scenarios:
- Primary tumors of the pancreas
- Primary tumors of the bile duct and ampulla
- Metastatic colorectal cancers to the liver
- Subjects must have disease resectable with a standard pancreatectomy
(pancreaticoduodenectomy or distal pancreatectomy) or liver resection.
- Subjects may have received prior therapy, including neoadjuvant regimens.
- Subjects must have serum CA 19-9 elevations greater than the upper limit of normal but
less than 2500 U/mL.
- Age >18 years.
- ECOG performance status <1
- Subjects must have adequate organ and marrow function as defined below:
- leukocytes >3,000/mcL
- absolute neutrophil count >1,500/mcL
- platelets >90,000/mcL
- For subjects with Periampullary cancers that require a pancreaticoduodenectomy for
complete tumor extirpation:
- total bilirubin <10 ULN*
- AST(SGOT)/ALT(SGPT) <5 X institutional upper limit of normal
- creatinine <1.5X institutional upper limit of normal
- Subjects with periampullary cancers typically present with biliary
obstruction resulting in significant abnormalities in liver function tests
that do not reflect liver dysfunction. These values normalize after tumor
removal. They can be normalized pre-operatively with biliary stenting but
several large studies have demonstrated an increase in infectious
complications with drainage. As such, a practice standard has been to avoid
stenting until bilirubin level rises above 10 X ULN.
- For subjects with liver tumors (cholangiocarcinoma or metastatic colorectal cancer)
requiring a hepatectomy for complete tumor extirpation:
- total bilirubin <2.5 X institutional upper limit of normal*
- AST(SGOT)/ALT(SGPT) <5 X institutional upper limit of normal*
- creatinine <1.5X institutional upper limit of normal
- Liver abnormalities in this range are consistent with parenchymal
destruction from the tumor.
- For subjects with pancreas tumors that require a distal pancreatectomy for
extirpation:
- total bilirubin <1.5 X institutional upper limit of normal*
- AST(SGOT)/ALT(SGPT) <2 X institutional upper limit of normal*
- creatinine <1.5X institutional upper limit of normal
- Liver abnormalities in this range are consistent with pancreas cancer
destruction from the tumor.
- The effects of MVT-5873 on the developing human fetus are unknown. For this reason,
women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and for
the duration of study participation and for 3 months after completion of study
treatment. Should a woman become pregnant or suspect she is pregnant while she or her
partner is participating in this study, she should inform her treating physician
immediately.
- Ability of subject to understand and the willingness to sign a written informed
consent document.
EXCLUSION CRITERIA:
- Presence of disease outside the confines of a standard operation for subjects with
periampullary cancers (pancreatic and cholangiocarcinoma).
- Presence of disease outside the liver for subjects with intrahepatic/hilar
cholangiocarcinoma or metastatic colorectal cancer, other than a primary tumor for
subjects with metastatic colorectal cancer.
- Subjects who are receiving any other investigational agents.
- Fewer than 28 days (or 5 half-lives for systemic agents, whichever is shorter) from
prior anticancer therapy, including chemotherapy, hormonal, investigational, and or
biological therapies and irradiation.
- Uncontrolled inter-current illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study
requirements.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
301-496-2563
Phone: 888-624-1937
National Institutes of Health Clinical Center The National Institutes of Health (NIH) Clinical Center in...
Click here to add this to my saved trials
